Investigation of the Anti-tumor Effect of 2X-121 in Patients With Recurrent, Advanced Ovarian Cancer
Trial details
- Registry ID
- NCT03878849
- Drugs studied
- 2X-121
TrialRedline tracks 4 clinical trials sponsored by Allarity Therapeutics: 4 Phase 2.
Company identity has not yet been verified
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Investigation of the Anti-tumor Effect of 2X-121 in Patients With Recurrent, Advanced Ovarian CancerNCT03878849 | 2X-121 | Recruiting | 2027-03Estimated |
| Investigation of Anti-tumour Effect and Tolerability of the PARP Inhibitor 2X-121 in Patients With Metastatic Breast Cancer Selected by the 2X-121 DRPNCT03562832 | PARP inhibitor 2X-121 | Completed | 2024-04-01Actual |
| Irofulven in AR-targeted and Docetaxel-Pretreated mCRPC Patients With Drug Response Predictor (DRP®)NCT03643107 | Irofulven, Prednisolone 10 mg | Completed | 2021-10-01Actual |
| Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP.NCT04796324 | Ixabepilone Injection | Terminated | 2024-12-01Actual |
Names as written in the registry records.
NCT04796324 · Allarity Therapeutics
Before: Estimated. After: Actual.
Before: 60 participants (planned). After: 13 participants (actual).
Before: Suspended. After: Terminated.